IVIg and FcgRIIb in kids with ITP: Individualizing therapy
© 2018 by The American Society of Hematology In this issue of Blood, Heitink-Pollé et al present the long-awaited results of a very important recent study, the TIKI (treatment with or without IV immunoglobulin [IVIg] for kids with immune thrombocytopenia [ITP]) trial: a randomized, controlled trial comparing IVIg to observation in children with ITP at diagnosis, with the primary end point of evaluating the rate of chronic ITP in treated and untreated children.
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency